Igor Klepikov*

Professor, Retired, Renton, WA, USA

*Corresponding Author: Igor Klepikov, Professor, Retired, Renton, WA, USA.

Received: September 16, 2024; Published: October 22, 2024

Abstract

First and emergency aid in acute diseases is the driving force of further treatment, determining its success. According to established traditions, in which the main role in the treatment of acute pneumonia is given to antibiotics, the latter are considered a universal remedy, which is also a method of first aid. Distortions of views on the nature of the disease and established stereotypes of providing assistance require waiting for the results of such treatment for 48-72 hours, which is unacceptable in conditions of rapidly progressing inflammatory changes. Additional means of helping such patients do not have a pathogenetic basis and are not able to change the situation. An analysis of the causes and ways out of this impasse is presented.

 Keywords: Acute Pneumonia; Antibiotics; First Aid; Infusion Therapy; Etiology; Pathogenesis

References

1. World Health Organization. The top 10 causes of death (2020).
2. Laporte L., et al. “Ten-year trends in intensive care admissions for respiratory infections in the elderly”. Annals of Intensive Care 8 (2018): 84.
3. Kristin R Wise., et al. “Increased Long-Term Mortality in Patients Admitted to the Intensive Care Unit with Health-Care Associated Pneumonia”. medRxiv (2021): 2021.12.23.21267010.
4. Lakbar I., et al. “Association between mortality and highly antimicrobial-resistant bacteria in intensive care unit-acquired pneumonia”. Scientific Report 11 (2021): 16497.
5. Boëlle PY., et al. “Trajectories of Hospitalization in COVID-19 Patients: An Observational Study in France”. Journal of Clinical Medicine 9 (2020): 3148.
6. Cavallazzi R., et al. “The burden of community-acquired pneumonia requiring admission to ICU in the United States”. Chest 158 (2020): 1008-1016.
7. Cilloniz C., et al. “Pure viral sepsis secondary to community-acquired pneumonia in adults: risk and prognostic factors”. Journal of Infectious Disease 220 (2019): 1166-1171.
8. Lin CK., et al. “Serum vascular endothelial growth factor affects tissue fluid accumulation and is associated with deteriorating tissue perfusion and oxygenation in severe sepsis: a prospective observational study”. European Journal of Medical Research 28 (2023): 155.
9. Burkhart M. “Improving Sepsis Bundle Compliance in the Emergency Department”. The Eleanor Mann School of Nursing Student Works (2001).
10. Sepsis (2024).
11. Fleischmann C., et al. “Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations”. American Journal of Respiratory and Critical Care Medicine 193 (2016): 253-272.
12. Rudd KE., et al. “Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study”. Lancet 395 (2020): 200-211.
13. Vincent JL., et al. “Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis”. Critical Care 23 (2019): 196.
14. Rhee C., et al. “Prevalence, underlying causes, and preventability of sepsis-associated mortality in US acute care hospitals”. JAMA Network Open (2019): 2e187571.
15. “What Is Pulmonary Hypertension?". From Diseases and Conditions Index (DCI). National Heart, Lung, and Blood Institute. September (2008).
16. Colledge NR., et al. “Davidson's Principles and Practice of Medicine (21^st)”. Edinburgh: Churchill Livingstone/Elsevier (2010).
17. “Normal Hemodynamic Parameters - Adult". Edwards Lifesciences LLC. Archived from the original on 2010-11-10.
18. Olivia Vynn. “Cardiology secrets”. Chapter 41, p. 210. Adair Edition: 2, illustrated Published by Elsevier Health Sciences, (2001).
19. Schwiegk H. “Der Lungenentlastungsreflex”. Pflügers Archges Physiol 236 (1935): 206-219.
20. Inflammation
21. Chandrasoma P and Taylor CR. "Part A. "General Pathology", Section II. ""The Host Response to Injury", Chapter 3. "The Acute Inflammatory Response", sub-section "Cardinal Clinical Signs". Concise Pathology (3rd ed.). McGraw-Hill. OCLC 150148447 (2005).
22. I Klepikov. “Myths, Legends and Real Facts About Acute Lung Inflammation”. Cambridge Scholars Publishing. (2024): 338.
23. Aminov RI. "A brief history of the antibiotic era: lessons learned and challenges for the future". Frontiers in Microbiology 1 (2010): 134.
24. BD Huttner., et al. “COVID-19: don't neglect antimicrobial stewardship principles!” Clinical Microbiology and Infection 7 (2020): P808-810.
25. B Beovic., et al. “Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey”. Journal of Antimicrobial Chemotherapy dkaa 326 (2020).
26. Rawson TM., et al. “Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing [published online ahead of print, 2020 May 2]”. Clinical Infectious Disease (2020): ciaa 530.
27. C Cillóniz., et al. “Community-acquired pneumonia in outpatients: aetiology and outcomes”. European Respiratory Journal 4 (2012): 931-938.
28. Jain S., et al. “CDC EPIC Study Team Community-acquired pneumonia requiring hospitalization among U.S. adults”. The New England Journal of Medicine 373 (2015): 415-427.
29. С Castillo. “2020 IDCA/ATS Community-Acquired Pneumonia Guideline: more micro, less macrolide, no HCAP”. 15th Annual NW Regional Hospital Medicine Conference (2020).
30. JP Metlay., et al. “Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America”. American Journal of Respiratory and Critical Care Medicine7 (2019): e45-e67.
31. Martin-Loeches I., et al. “ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia”. Intensive Care Medicine 49 (2023): 615-632.

Citation

Citation: Igor Klepikov. “Why is First Aid Ineffective for Acute Pneumonia?”.Acta Scientific Medical Sciences 8.11 (2024): 115-121.

Copyright

Copyright: © 2024 Igor Klepikov. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.